CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.78
−1.46%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.30
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.52
- EPS estimate
- -$0.24
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -56.7%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $19
- PT range
- $12 – $23
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026